165 related articles for article (PubMed ID: 10757346)
1. Participation of endogenously produced interferon gamma in interleukin 4-mediated tumor rejection.
Nishihori H; Tsuji H; Wang H; Tahara H; Akiyama M; Ogawa Y; Matsushima K; Iwakura Y; Mukaida N
Hum Gene Ther; 2000 Mar; 11(5):659-68. PubMed ID: 10757346
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells engineered with IL-12 and IL-15 genes induce protective antibody responses in nude mice.
Orengo AM; Di Carlo E; Comes A; Fabbi M; Piazza T; Cilli M; Musiani P; Ferrini S
J Immunol; 2003 Jul; 171(2):569-75. PubMed ID: 12847220
[TBL] [Abstract][Full Text] [Related]
4. Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes.
Wang H; Nemoto-Sasaki Y; Kondo T; Akiyama M; Mukaida N
Int Immunopharmacol; 2003 May; 3(5):627-42. PubMed ID: 12757733
[TBL] [Abstract][Full Text] [Related]
5. Alloantigen-reactive Th1 development in IL-12-deficient mice.
Piccotti JR; Li K; Chan SY; Ferrante J; Magram J; Eichwald EJ; Bishop DK
J Immunol; 1998 Feb; 160(3):1132-8. PubMed ID: 9570526
[TBL] [Abstract][Full Text] [Related]
6. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
7. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells.
Tasaki K; Yoshida Y; Maeda T; Miyauchi M; Kawamura K; Takenaga K; Yamamoto H; Kouzu T; Asano T; Ochiai T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2000 Feb; 7(2):247-54. PubMed ID: 10770633
[TBL] [Abstract][Full Text] [Related]
9. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
10. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
11. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
Fallarino F; Uyttenhove C; Boon T; Gajewski TF
J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
13. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
14. IFN-gamma IL-2, and IL-4 mRNA expression in the skin and draining lymph nodes of BALB/c mice repeatedly infested with nymphal Ixodes ricinus ticks.
Mbow ML; Rutti B; Brossard M
Cell Immunol; 1994 Jun; 156(1):254-61. PubMed ID: 8200040
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
Hock H; Dorsch M; Kunzendorf U; Qin Z; Diamantstein T; Blankenstein T
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2774-8. PubMed ID: 8464888
[TBL] [Abstract][Full Text] [Related]
16. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Stoppacciaro A; Forni G; Colombo MP
Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
[TBL] [Abstract][Full Text] [Related]
17. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
19. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
[TBL] [Abstract][Full Text] [Related]
20. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
